Read about our partnership opportunities
We know we can’t reach our goal of improving patient access to much needed biologics without help, so we have partnered with some of the largest biopharmaceutical companies on the planet to ensure our biosimilars reach those that need them most.
Our current partnerships
We have entered a global commercialization agreement with Sandoz AG for the commercialization of our natalizumab biosimilar
Under the agreement, we are responsible for the development, manufacturing and supply of the collaboration biosimilar. Sandoz have global commercialisation rights.
We have entered into a joint venture company, Bioeq, with Santo Holding AG (Strüngmann Group) for the development of the biosimilar Ranibizumab.
The biosimilar was originally licensed from Formycon AG and subsequently developed by Bioeq AG
Our joint venture company, Bioeq, has entered into a commercialization agreement with Teva for the biosimilar Ranibizumab
Teva Pharmaceutical Industries Ltd have commercialisation rights to the biosimilar candidate of the ophthalmological drug Ranibizumab (Lucentis®) in Europe, Canada, Israel and New Zealand.
Our areas of interest
We focus on developing biosimilars that will be first to market or where there is a significant market potential. These can be either for blockbuster originators or niche disease areas. As a company we consistently invest in the start of new biosimilar developments every year based upon expert market analysis, clinical evaluation, and an extensive manufacturing assessment.
Our approach to partnering
Currently, there is no company on the Polish market with scale comparable to ours and with a similar business model. We are able to handle biosimilars from the concept stage to large scale production. We are currently developing 10 molecules and in addition, have 2 biosimilars approved in multiple markets. These leading biosimilars are partnered with multiple companies for marketing rights to different territories.
For more information please get in touch.